Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is a biotechnology company dedicated to developing a pipeline of disease-modifying antibodies for the treatment of inflammatory diseases, including Crohn's disease and ulcerative colitis. The platform generates potent orally available antibodies designed to maintain activity throughout the intestinal system. The lead program, SOR102, is in development for the treatment of inflammatory bowel disease (IBD). SOR102 simultaneously inhibits TNFa and IL-23, two clinically validated drivers of IBD. This unique approach combines the clinical impact of injectable antibody therapies with the benefits of oral administration, resulting in targeted activity, negligible systemic exposure, and minimal immunogenicity.